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796Objective: Many patients with non–small cell lung cancer have positive mediastinal lymph nodes on
preoperative positron emission tomography (PET) but do not have mediastinal involvement after surgery.
The prognostic significance of this discordance was assessed.
Methods: This Institutional Review Board–approved study evaluated patients treated with upfront surgery at
Duke Cancer Institute (Durham, NC) for non–small cell lung cancer from 1995 to 2008. Those staged with
PETwith pN0-1 disease after negative invasive mediastinal assessment were included. Mediastinal lymph nodes
were scored as positive or negative based on visual analysis of the preoperative PET. Clinical outcomes of the
PET-positive and PET-negative cohorts were estimated using the Kaplan-Meier method and compared using
a log-rank test. Prognostic factors were assessed using a multivariate analysis.
Results: A total of 547 patients were assessed, of whom 105 (19%) were PET positive in the mediastinum. The
median number of mediastinal lymph node stations sampled was 4 (range, 1-9). The 5-year risk of local
recurrence was 26% in PET-positive versus 21% in PET-negative patients (P ¼ .50). Patterns of local failure
were similar between the 2 groups. Distant recurrence (35% vs 29%; P ¼ .63) and overall survival (44% vs
54%; P¼ .52) were comparable for PET-positive and PET-negative patients. Onmultivariate analysis, a positive
PETwas not significant for local recurrence (hazard ratio [HR], 1; P¼ 1), distant recurrence (HR, 0.82; P¼ .42),
or overall survival (HR, 1.08; P ¼ .62).
Conclusions: Patients with positive mediastinal lymph nodes on preoperative PET, but negative on
histologic analysis, are not at increased risk of disease recurrence. Pathologic staging remains the standard.
(J Thorac Cardiovasc Surg 2013;146:796-801)Earn CME credits at
http://cme.ctsnetjournals.org
Fluorodeoxyglucose positron emission tomography (FDG-
PET) is commonly used in the diagnosis and staging of
non–small cell lung cancer (NSCLC). PET has improved
preoperative staging of NSCLC in several trials.1-3 However,
in the assessment of mediastinal lymph nodes, PET has
been associated with a significant false-positive rate. Positive
predictive values for PET are reported to range from 69% to
90%, with similar values for integrated PET–computed
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The Journal of Thoracic and Cardiovascular Surghave positive mediastinal lymph nodes on preoperative PET
but will not have mediastinal disease at surgery.
It is unclear whether positive PET findings are prognos-
tic, despite negative surgical findings. One study showed
that patients with positive mediastinal lymph nodes by
PET, which were negative at histologic analysis, were at
higher risk of disease recurrence.9 On the other hand,
another study showed that overall and nodal stage, deter-
mined by PET, was correlated with survival, but no
additional predictive value was obtained when histologic
stage was also known.10 We sought to explore this issue
further by examining whether patients with positive lymph
nodes in the mediastinum by PET, but histologically
negative after surgery, are at higher risk for disease
recurrence, particularly in the mediastinum.METHODS
This Institutional Review Board–approved study evaluated all patients
who underwent initial surgery for NSCLC at Duke Cancer Institute
(Durham, NC) between 1995 and 2008 (patients receiving preoperative
chemotherapy and/or radiotherapy were excluded). Those patients with
preoperative PET or PET-CT imaging at our institution with pathologic
T1-3 N0-1 disease were identified. All patients had mediastinal lymph
nodes assessed at mediastinoscopy and/or surgery. Patients were excluded
if they had positive surgical margins or received postoperative radiation
therapy because these 2 factors are known to affect the risk of local
recurrence. We also excluded patients who died within 30 days of surgeryery c October 2013
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Sor had a primary lung cancer that was not FDG-avid. Patients who received
adjuvant chemotherapy were included.
PET imagingwith 18F FDGwas performed using a GEAdvance scanner
(General Electric Healthcare, Milwaukee, Wis) from 1995 to 2003, and
the images were reviewed with a concurrent computed tomographic
(CT) scan. From 2003 to 2008, a Discovery ST PET/CT scanner (General
Electric Healthcare) was used, and PET images were reviewed with a non–
contrast-enhanced CT. Fasting patients with a blood glucose level of less
than 200 mg/dL received an intravenous FDG injection approximately
60 minutes before imaging. The acquisition time was 3 to 4 minutes per
bed position, depending on body weight. PET images were reconstructed
with corrections for attenuation (CT based or based on rotating
germanium-68 source for PET only), scatter, random events, and dead
time. Filtered back-projection was used before 1999, and 2 iterations of
ordered subset expectation maximization were used subsequently.
All PET studies were interpreted by attending nuclear medicine
physicians. Although not standardized, lymph nodes were scored as
positive when, by visual analysis, they were associated with FDG uptake
higher than mediastinal blood pool levels, with correspondence to a lymph
node detected on CT. For this study, patients were classified as PET positive
or PET negative in the mediastinum, based on the interpretation recorded in
the original PET report. Standardized uptake value (SUV) thresholds were
not used to define PET positivity because there is no acceptable cutoff value
for determining positive versus negative. The International Association for
the Study of Lung Cancer lymph node map was used to delineate the
anatomic boundaries of mediastinal lymph node stations for mapping of
PET-positive lymph nodes.11 Staging was recorded using the 7th edition
of the American Joint Committee on Cancer tumor, node, metastasis
(TNM) classification system.12
All patients underwent an R0 resection with mediastinal lymph node
sampling and/or dissection. Between 1995 and 1997, lung tumor specimens
were interpreted by multiple pathologists at Duke University. After 1998,
most specimens were interpreted by a single pathologist with a special
interest in pulmonary pathology. All patients had routine postsurgical
surveillance with imaging, including chest CT, but testing was not
standardized.Disease recurrence at the surgical resectionmargin, ipsilateral
hilum, and/or mediastinum was considered a local recurrence. All other
sites of recurrence were considered distant metastases. Sites of local recur-
rence, including specific mediastinal lymph node stations, were identified.
The objective of this study was to determine if patients with positive
lymph nodes in the mediastinum by PET, but negative by pathologic
analysis, were at increased risk of disease progression. The primary end
point of interest was time to local recurrence. Patterns of failure between
PET-positive and PET-negative patients were also assessed.
Statistical Analysis
Study data were collected and managed using REDCap electronic
data capture tools hosted at Duke University.13 The Fischer exact and
Mann-Whitney U tests were used to compare patient and treatment
characteristics between PET-positive and PET-negative cohorts. The
Kaplan-Meier product-limit methodwas used to estimate 5-year recurrence
probabilities and confidence intervals.14 Time to local failure and time to
distant failure were calculated from the date of surgery to the date of localThe Journal of Thoracic and Caor distant recurrence, respectively. Local and distant recurrences were
scored independently (ie, patients developing a distant recurrence were
not censored for local failure, but were assessed for local failure until the
date of last follow-up or death).
A Cox multivariate analysis was also performed to assess for clinical
and pathologic factors associated with an increased risk of local failure
after resection, including mediastinal PET status. Variables were included
in the multivariate model if they achieved a P  .15 on univariate analysis.
All statistical tests were 2 sided, and P<.05 was considered statistically
significant. SAS 9.1 statistical software (SAS Institute, Inc, Cary, NC)
was used for statistical analyses.RESULTS
There were 547 patients who met the inclusion criteria.
The median follow-up was 29 months (range, 1-170
months). Patients were pN0 in 469 (86%) and pN1 in 78
(14%). Adjuvant chemotherapy was administered to 57
(10%). Other patient characteristics and surgical/pathologic
details are shown in Table 1.
Preoperative imagingconsisted ofPETwith concurrentCT
(n¼ 269) or integrated PET-CT (n¼ 278). The preoperative
PET was positive in the mediastinum in 105 (19%) of the
patients and negative in 442 (81%) of the patients. Among
PET-positive patients, the median number of mediastinal sta-
tions with hypermetabolic lymph nodes was 1 (range, 1-7).
Themost commonmediastinal lymph node stations involved
were 4R (n¼ 58), 5 (n¼ 32), and 7 (n¼ 26). The number of
patients with positive lymph nodes in other mediastinal
stations was as follows: 2R (n ¼ 9), 2L (n ¼ 4), 3 (n ¼ 8),
4L (n ¼ 15), 6 (n ¼ 3), and 8 (n ¼ 4).
Mediastinal assessment included mediastinoscopy alone
(n¼ 83), video-assisted thoracoscopic surgery/thoracotomy
alone (n¼ 99), or both (n¼ 365). Themedian number ofme-
diastinal lymph node stations examinedwas 4 (range, 1-8) in
PET-positive patients and 3 (range, 1-9) in PET-negative pa-
tients (P¼ .042). At least 3 mediastinal lymph node stations
were sampled in 88% of PET-positive patients and 78% of
PET-negative patients. Of lymph node stations positive on
preoperative PET imaging, 70% (113/161) were sampled
at mediastinoscopy and/or surgery. The most common
lymph node station hypermetabolic on PET, but not sampled
during the preoperativework-up and/or at surgery, was level
5 (21/48). In 81% (17/21) of cases, when level 5 was not
sampled, the patient had a right-sided primary tumor.
Local disease recurrence was identified in 78 patients.
The 5-year risk of local recurrence in all patients was 22%
(95% confidence interval [CI], 17%-27%). There was no
significant difference in risk of local recurrence between
the PET-positive patients and PET-negative patients (26%
vs 21%; P ¼ .50) (Figure 1). This was true in both the
pN0 subgroup (P ¼ .63) and the pN1 subgroup (P ¼ .97).
Patterns of local recurrence were similar between
PET-positive and PET-negative patients (Table 2). Among
the 105 PET-positive patients, 14 had a local disease
recurrence in the mediastinum. Imaging studies could berdiovascular Surgery c Volume 146, Number 4 797
TABLE 1. Patient and treatment characteristics
Parameter All (n ¼ 547)
PET mediastinum findings
P valuePositive (n ¼ 105) Negative (n ¼ 442)
Sex .3858
Male 280 (51) 58 (55) 222 (50)
Female 267 (49) 47 (45) 220 (50)
Age, median (range), y 68 (39-93) 69 (40-86) 68 (39-93) .6457
PET imaging technique .5885
PET 269 (49) 49 (47) 220 (50)
PET-CT 278 (51) 56 (53) 222 (50)
Mediastinoscopy 448 (82) 93 (89) 355 (80) .0491
Surgical procedure .1192
Wedge/segmentectomy 94 (17) 20 (19) 74 (17)
Lobectomy* 428 (78) 76 (72) 352 (80)
Pneumonectomy 25 (5) 9 (9) 16 (3)
Surgical approach .0456
Open 217 (40) 51 (49) 166 (38)
VATS 330 (60) 54 (51) 276 (62)
No. of mediastinal LN stations
sampled, median (range)
4 (1-9) 4 (1-8) 3 (1-9) .0416
Histology .1372
Adenocarcinoma 264 (49) 42 (40) 222 (51)
Squamous cell carcinoma 208 (38) 47 (45) 161 (36)
Large-cell carcinoma 38 (7) 11 (11) 27 (6)
NSCLC NOS 30 (6) 4 (4) 26 (6)
Histologic differentiation .0873
Well 46 (9) 4 (4) 42 (10)
Moderate 245 (45) 43 (41) 202 (46)
Poor 187 (34) 45 (43) 142 (32)
Lymphovascular space invasion 111 (20) 27 (26) 84 (19) .1377
Visceral pleural involvement 126 (23) 22 (21) 104 (24) .6086
Pathologic nodal stage .5381
N0 469 (86) 88 (84) 381 (86)
N1 78 (14) 17 (16) 61 (14)
Pathologic stage .0006
IA 242 (44) 38 (36) 204 (46)
IB 146 (27) 23 (22) 123 (28)
IIA 98 (18) 20 (19) 78 (18)
IIB 49 (9) 20 (19) 29 (6)
IIIA 12 (2) 4 (4) 8 (2)
Postoperative chemotherapy 57 (10) 17 (16) 40 (9) .0486
Values are given as number (%) unless otherwise indicated. PET, Positron emission tomography; CT, computed tomography; VATS, video-assisted thoracoscopic surgery;
LN, lymph node; NSCLC, non–small cell lung cancer; NOS, not otherwise specified. *Lobectomy, bilobectomy, or sleeve lobectomy.
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Sretrieved in 13 of these patients to determine the specific
site(s) of mediastinal failure. In 11 of the 13 patients, the
site of mediastinal failure correlated to the lymph node sta-
tion positive on preoperative PET. Most (10/11) of these pa-
tients had undergone surgical sampling of that mediastinal
lymph node station at surgery.
For all patients, the 5-year risk of developing distant
metastases was 30% (95% CI, 25%-35%) and the 5-year
overall survival was 52% (95% CI, 47%-57%). No differ-
ences in risk of distant recurrence (35% vs 29%; P ¼ .63)
or overall survival (44% vs 54%; P ¼ .52) (Figure 2) were
noted between the PET-positive and PET-negative groups
(Figure 2).798 The Journal of Thoracic and Cardiovascular SurgOn multivariate analysis, PET positivity in the mediasti-
num was not associated with increased risk of local
recurrence (hazard ratio [HR], 1.00; P ¼ .99), distant
recurrence (HR, 0.82; P ¼ .42), or overall survival
(HR, 1.08; P ¼ .62) (Table 3).
For the subset of patients (n ¼ 453) undergoing at least
a lobectomy (excluding wedge or segmentectomy), there
continued to be no difference in 5-year risk of local disease
recurrence, distant recurrence, or overall survival between
the PET-positive and PET-negative cohorts. On multivariate
analysis, PET positive in the mediastinum was not
associated with increased risk of local recurrence in this
subgroup (HR, 0.78; 95% CI, 0.41-1.48; P ¼ .45).ery c October 2013
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FIGURE 1. Kaplan-Meier curves with 95% confidence intervals compa-
ring freedom from local recurrence for patients with pathologic N0-N1
non–small cell lung cancer with either positron emission tomographic
(PET)–positive (dotted line) or PET-negative (solid line) mediastinal
lymph nodes on preoperative PET.
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FIGURE 2. Kaplan-Meier curves with 95% confidence intervals
comparing overall survival for patients with pathologic N0-N1 non–small
cell lung cancer with either positron emission tomographic (PET)–positive
(dotted line) or PET-negative (solid line) mediastinal lymph nodes on
preoperative PET.
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SCurrent guidelines recommend systematic sampling of at
least 3 lymph node stations in early-stage NSCLC.15,16 In
the subset of patients (n ¼ 439) who had 3 or more lymph
node stations sampled, there was no difference in 5-year
rates of local recurrence (23% vs 22%; P ¼ .94), distant
recurrence (34% vs 30%; P ¼ .88), and overall survival
(48% vs 52%; P ¼ .44) for PET-positive versus
PET-negative patients, respectively. Also, contralateral
mediastinal disease is rare in patients with early-stage,
right-sided tumors.17 After excluding the patients with
right-sided tumors and contralateral PET-positive mediasti-
nal lymph nodes (n ¼ 22), there continued to be no
difference in clinical outcomes.DISCUSSION
In this analysis, we observed that 19% of patients with
NSCLC were apparently overstaged in the mediastinumTABLE 2. Patterns of local failure
Parameter*
All
(n ¼ 547)
PET mediastinum findings
Positive
(n ¼ 105)
Negative
(n ¼ 442)
Local recurrence (all sites) 78 (14) 17 (16) 61 (14)
Mediastinum 54 (69) 14 (82) 40 (66)
Ipsilateral hilum 24 (31) 7 (41) 17 (28)
Stump/surgical line 24 (31) 4 (24) 20 (33)
PET, Positron emission tomography. *Values are given as number (%). Total percent-
ages add up to more than 100% because some patients had multiple sites of failure.
The Journal of Thoracic and Caby PET. Because surgery is the gold standard, it is assumed
that this represents false-positive findings (ie, benign lymph
nodes with FDG avidity). It is also feasible that the PET
accurately identified malignant lymph nodes, but either
the involved lymph node was not removed at surgery or
the pathologic assessment was inaccurate. However, we
found that patients with positive mediastinal findings on
preoperative PET, but with pathologic N0-N1 disease, are
at no higher risk of disease recurrence or death compared
with patients with a negative preoperative PET. Patterns
of local recurrence were also not different between the
2 cohorts.
The false-positive rate of PET in this study is similar to
reports elsewhere in the literature. In large reviews, the
false-positive rate for PET in the mediastinum is 10% to
31%.4-6 An integrated PET-CT has been more accurate
than PET in determining nodal status in both patient and
nodal analyses.18 However, such as PET alone, PET-CT is
associated with false-positive findings in the mediasti-
num.7,8 There are multiple possible explanations for
false-positive PET findings. These include nonmalignant
lung diseases, such as tuberculosis, bacterial and fungal
lung infections, and sarcoidosis.19,20 In a previous study
performed at Duke, pneumonia, granulomatous disease,
and silicosis were specifically associated with false-
positive PET findings.21 Furthermore, PET interpretation
is subject to significant interobserver and intraobserver
variations.22 Some of the variation may be explained byrdiovascular Surgery c Volume 146, Number 4 799
TABLE 3. Univariate and multivariate analyses for local recurrence
Factors*
Univariate analysis Multivariate analysis
Hazards ratio 95% CI P value Hazards ratio 95% CI P value
Age 0.99 0.96-1.01 .2767
Sex
Female 1.16 0.74-1.81 .5209
Male
PET-positive mediastinum 1.20 0.70-2.06 .5029 0.96 0.55-1.69 .8993
Surgical procedure
Lobectomy 1.47 0.84-2.58 .1816 2.68 1.42-5.05 .0022
Wedge/segmentectomy
Surgical approach
Open 0.81 0.52-1.26 .3517
VATS
No. of mediastinal LNs sampled 0.96 0.83-1.11 .6099
Stage overally — — <.0001 — — <.0001
Histology
Nonsquamous 2.03 1.30-3.19 .0020 1.78 1.13-2.82 .0133
Squamous or large cell
Lymphovascular invasion 1.01 0.58-1.75 .9785
Visceral pleural invasion 1.96 1.22-3.15 .0057 1.44 0.83-2.48 .1920
Adjuvant chemotherapy 1.66 0.91-3.01 .0958 1.10 0.57-2.10 .7783
CI, Confidence interval; VATS, video-assisted thoracoscopic surgery; LN, lymph node; PET, positron emission tomography. *The first factor level listed is the reference set
(when multiple factors are listed). yThe multivariate analysis hazards ratios for stages are as follows: IB vs IA, 1.51; IIA vs IA, 4.60; IIB vs IA, 4.24; and IIIA vs IA, 1.30.
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variation in scanners and their accuracy/resolution.19
Our study was limited to patients who underwent
invasive staging of the mediastinum during mediastino-
scopy and/or surgery. The median number of mediastinal
lymph node stations sampled was 4, and 80% of patients
had 3 or more mediastinal lymph nodes sampled. Patients
with PET-positive mediastinal lymph nodes had more
extensive evaluation of the mediastinum, suggesting
awareness of the surgeon of the PET-positive mediastinal
lymph nodes or differences in other prognostic factors
(eg, T stage). Evidence-based guidelines recommend
pathologic evaluation of a minimum of 3 mediastinal lymph
node stations.15,16 To control for variations in mediastinal
assessment, we performed a subset analysis including
patients who had 3 or more lymph node stations sampled,
thus eliminating all patients who were not adequately
surgically staged in the mediastinum (patients more likely
to have false-negative invasive staging). In this analysis,
we continued to see no significant difference in outcomes
between PET-negative and PET-positive patients. These
data suggest that PET does not provide additional prognos-
tic data beyond the pathologic stage when patients are
adequately staged at surgery.
Guidelines also recommend that discrete mediastinal
lymph nodes positive on preoperative PET should be
sampled pathologically.16,23 Although 88% of PET-
positive patients had 3 or more mediastinal lymph node
stations sampled invasively in our series, 30% of discrete
mediastinal lymph node stations positive on preoperative800 The Journal of Thoracic and Cardiovascular SurgPET were not sampled pathologically. There are several
possible explanations for this discrepancy: (1) no lymph
nodes identified during invasive assessment at a suspicious
mediastinal station, (2) an unusual lymph node pattern that
is discounted (PET-positive findings in level 5, with
right-sided tumors), (3) confusion regarding which lymph
node stations were deemed suspicious, and (4) errors in
recording the site of a positive lymph node (radiology
and/or pathology report). Furthermore, sampling the
hypermetabolic lymph node within a station is vital, but
often difficult to confirm, especially retrospectively.
Limited research has assessed the prognostic significance
of discordant nodal stages determined by PET and
pathologic assessment. One retrospective study showed
that both tumor and nodal stages, determined by visual
PET interpretation, were correlated with survival.10 How-
ever, when histologic stage was included in a multivariate
model, PET provided no additional prognostic information.
A more recent study by Xie and colleagues9 specifically
focused on patients with pathologic N0/N1 NSCLC. They
demonstrated increased rates of local-regional and distant
failures in patients with positivemediastinal findings on pre-
operative PET, compared with thosewith a negative PET. In
their multivariate analysis, PET positivity in the mediasti-
num was significant for distant failure and was marginally
significant for local-regional failure (HR, 1.9; P ¼ .093).
In our analysis, we did not see significant differences in local
recurrence, distant recurrence, or overall survival between
the PET-positive and PET-negative cohorts. The most plau-
sible explanation for the discordant results presented by Xieery c October 2013
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tients in their study, only 13 were PET positive in the medi-
astinum. Thus, their findings were based on a few events. In
contrast, we studied 547 patients, of which 105 were PET
positive in the mediastinum. It is also possible that differ-
ences in the distribution of stage and PET findings contrib-
uted to the discordant results. Xie and colleagues9 had more
patients with pN1 disease, and these patients were more
likely to have a positive PET than patients who were pN0.
In contrast, in our study, patients with pN0 and pN1 disease
had a similar likelihood of having a positive PET. Other pos-
sible reasons for discordant results could include differences
in PET interpretation, thoroughness of mediastinal sam-
pling/dissection, and/or extent of pathologic assessment.
Our study has several clinical implications. Guidelines
recommend invasive assessment of mediastinal lymph
node stations positive on staging PET. With a 19%
false-positive rate, our study supports this guideline.
Furthermore, our results suggest that histologic findings
should be the primary means of assessing prognosis after
surgery and guiding adjuvant treatment decisions, even
when PET findings appear to conflict with the final
pathologic assessment. Thus, PET positivity by itself
should not be used as a criterion for adjuvant chemotherapy
or radiation therapy when mediastinal lymph nodes are
pathologically negative.
There are inherent limitations to this study based on its
retrospective design. We used the original PET interpreta-
tion to score patients as having PET-positive mediastinal
lymph nodes. This would have the most clinical relevance
because the original interpretation was the tool used by
clinicians making treatment decisions. We did not use
SUVmax data in this analysis because no clear cutoff level
has been established for determining positive versus
negative. In the study by Xie and colleagues,9 SUVmax
of the mediastinal lymph nodes was not prognostic for
local/regional or distant failure. To the best of our know-
ledge, this study represents the largest study of its kind
evaluating discordant PETand histologic results in NSCLC.
CONCLUSIONS
Positive mediastinal lymph nodes on preoperative PET
do not provide any additional prognostic information in
patients found to be pathologically negative after curative
surgery. Thus, pathologic staging should remain the stan-
dard when making adjuvant treatment recommendations.
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